Uric acid in atherosclerosis and cardiovascular diseases: innocent bystander or ruthless killer?

Abstract

Medical attention to uric acid (UA) has been increasing in recent years, mainly because this molecule has been shown to be associated with increased cardiovascular risk, both in the general population and in the hypertensive patients. A growing body of clinical and experimental data supports this view and prompts reconsideration of the role of UA in the development of atherosclerosis and the genesis of cardiovascular disease. It is known that this substance, in certain plasma concentrations, induces increased oxidative stress, a chronic inflammatory state, and a whole series of other modifications that are potentially deleterious at the cardiovascular level leading to hypertension, atherosclerosis, atrial fibrillation (AF), and other metabolic changes such as diabetes, metabolic syndrome, non-alcoholic fatty liver disease and kidney failure. Despite this epidemiologic and mechanistic evidence, the current guidelines from international cardiology scientific societies do not give precise indications in this regard, and some of them only suggest UA evaluation as part of an initial screening of the hypertensive patient. The purpose of this review is to briefly describe the main clinical and epidemiological evidence supporting the role of hyperuricemia as a possible emerging cardiovascular risk factor and to analyze the potential pathophysiological mechanisms through which elevated UA levels may exert a detrimental effect on the cardiovascular system.

Keywords

Hyperuricemia / inflammation / cardiovascular risk / atherosclerosis / cardiovascular diseases

References

[1] Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016; 213: 8-14. Erratum in: Int J Cardiol. 2023;387:131126.

[2] Zhang C, Li L, Zhang Y, Zeng C. Recent advances in fructose intake and risk of hyperuricemia. Biomed Pharmacother. 2020; 131: 110795.

[3] Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020; 12: 3167-81.

[4] Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci. 2021; 22: 12394.

[5] Yang X, Gu J, Lv H, Li H, Cheng Y, Liu Y, et al. Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor. Biomed Pharmacother. 2019; 109: 1163-70.

[6] Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018; 278: 226-31.

[7] Xiao J, Zhang XL, Fu C, Han R, Chen W, Lu Y, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the toll-like receptor 4-mediated pathway. Int J Mol Med. 2015; 35: 1347-54.

[8] Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27: 1174-81.

[9] Katsiki N, Kouvari M, Panagiotakos DB, Borghi C, Chrysohoou C, Mikhailidis DP, et al. The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. Rev Cardiovasc Med. 2021; 22: 991-1001.

[10] Cicero AF, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C; Brisighella Heart Study Group. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur J Intern Med. 2017; 37: 38-42.

[11] Kuwabara M, Kuwabara R, Hisatome I, Niwa K, Roncal-Jimenez CA, Bjornstad P, et al. “Metabolically healthy” obesity and hyperuricemia increase risk for hypertension and diabetes: 5-year Japanese Cohort Study. Obesity (Silver Spring). 2017; 25: 1997-2008.

[12] Li F, Chen S, Qiu X, Wu J, Tan M, Wang M. Serum uric acid levels and metabolic indices in an obese population: a cross-sectional study. Diabetes Metab Syndr Obes. 2021; 14: 627-35.

[13] Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez CA, Andres-Hernando A, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017; 69: 1036-44.

[14] Kuwabara M, Borghi C, Cicero AFG, Hisatome I, Niwa K, Ohno M, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol. 2018; 261: 183-8.

[15] Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA. Serum uric acid and acute kidney injury: a mini review. J Adv Res. 2017; 8: 529-36.

[16] Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018; 71: 851-65.

[17] Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the framingham heart study. Ann Intern Med. 1999; 131: 7-13.

[18] Lu J, Sun M, Wu X, Yuan X, Liu Z, Qu X, et al. Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis. FEBS J. 2019; 286: 1346-59.

[19] Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16: 380-90.

[20] Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021; 397: 1843-55. Erratum in: Lancet. 2021; 397:1808.

[21] Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007-2016. Arthritis Rheumatol. 2019; 71: 991-9.

[22] Borghi C, Agnoletti D, Cicero AFG, Lurbe E, Virdis A. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. Hypertension. 2022; 79: 1927-36.

[23] Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, et al. Uric acid and hypertension: an update with recommendations. Am J Hypertens. 2020; 33: 583-94. Erratum in: Am J Hypertens. 2020; 33:1150.

[24] Davis NS. The cardio-vascular and renal relations and manifestations of gout. JAMA. 1897; XXIX: 261-2.

[25] Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951; 34: 1421-31.

[26] Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966; 275: 457-64.

[27] Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008; 392: 1-7.

[28] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359: 1811-21. Erratum in: N Engl J Med. 2010;362:2235.

[29] Kleber ME, Delgado G, Grammer TB, Silbernagel G, Huang J, Krämer BK, et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol. 2015; 26: 2831-8.

[30] Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010; 12: 118-24.

[31] Borghi C, Piani F. Uric acid and risk of cardiovascular disease: a question of start and finish. Hypertension. 2021; 78: 1219-21.

[32] Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014; 18: 1295-306.

[33] Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol. 2020; 11: 582680.

[34] Kahn HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J. 1972; 84: 171-82.

[35] Visco V, Pascale AV, Virtuoso N, Mongiello F, Cinque F, Gioia R, et al. Serum uric acid and left ventricular mass in essential hypertension. Front Cardiovasc Med. 2020; 7: 570000.

[36] Huang Y, Chen S, Yang X, Lin Z, Yan L, Wang F, et al. Impact of serum uric acid on subclinical myocardial injury in general population. Nutr Metab Cardiovasc Dis. 2022; 32: 641-7.

[37] Hung YH, Huang CC, Lin LY, Chen JW. Uric acid and impairment of renal function in non-diabetic hypertensive patients. Front Med (Lausanne). 2022; 8: 746886.

[38] Johnson RJ, Sanchez Lozada LG, Lanaspa MA, Piani F, Borghi C. Uric acid and chronic kidney disease: still more to do. Kidney Int Rep. 2022; 8: 229-39.

[39] McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017; 12: 807-16.

[40] King C, Lanaspa MA, Jensen T, Tolan DR, Sánchez-Lozada LG, Johnson RJ. Uric acid as a cause of the metabolic syndrome. In: Uric acid in chronic kidney disease. S.Karger AG; 2018. pp. 88-102.

[41] Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH gidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) . J Hypertens. 2023; 41: 1874-2071. Erratum in: J Hypertens. 2024;42:194.

[42] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39: 3021-104. Erratum in: Eur Heart J. 2019;40:475.

[43] Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42: 3227-337.

[44] Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012; 60: 1148-56.

[45] Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014; 64: 1102-7.

[46] Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, et al. Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial. Arthritis Rheumatol. 2021; 73: 1514-22.

[47] Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009; 2: 556-62.

[48] Leyva F, Chua TP, Godsland IF, Coats AJ, Anker SD. Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure. Heart. 1999; 82: 348-51.

[49] Leyva F, Chua TP, Anker SD, Coats AJ. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism. 1998; 47: 1156-9.

[50] Kumrić M, Borovac JA, Kurir TT, Božić J. Clinical implications of uric acid in heart failure: a comprehensive review. Life (Basel). 2021; 11: 53.

[51] Terada LS, Guidot DM, Leff JA, Willingham IR, Hanley ME, Piermattei D, et al. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci U S A. 1992; 89: 3362-6.

[52] Yan M, Chen K, He L, Li S, Huang D, Li J. Uric acid induces cardiomyocyte apoptosis via activation of calpain-1 and endoplasmic reticulum stress. Cell Physiol Biochem. 2018; 45: 2122-35.

[53] Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998; 19: 1814-22.

[54] Eisen A, Benderly M, Goldbourt U, Haim M. Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease? Clin Cardiol. 2013; 36: 110-6.

[55] Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002; 106: 3073-8.

[56] Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity: evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol. 2001; 38: 1850-8.

[57] Misra D, Zhu Y, Zhang Y, Choi HK. The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study. Semin Arthritis Rheum. 2011; 41: 471-6.

[58] Palazzuoli A, Ruocco G, De Vivo O, Nuti R, McCullough PA. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction. Am J Cardiol. 2017; 120: 1146-50.

[59] Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014; 16: 15-24.

[60] Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009; 266: 558-70.

[61] Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al.; JCARE-CARD Investigators. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol. 2011; 151: 143-7.

[62] Huang G, Qin J, Deng X, Luo G, Yu D, Zhang M, et al. Prognostic value of serum uric acid in patients with acute heart failure: a meta-analysis. Medicine (Baltimore). 2019; 98: e14525.

[63] Mantovani A, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, et al.; GISSI-HF Investigators. Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. Metabolism. 2018; 83: 205-15.

[64] Deis T, Rossing K, Ersbøll MK, Wolsk E, Gustafsson F. Uric acid in advanced heart failure: relation to central haemodynamics and outcome. Open Heart. 2022; 9: e002092.

[65] Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007; 9: 518-24.

[66] Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M, et al. The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol. 2016; 68: 384-91.

[67] Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997; 18: 858-65.

[68] Zheng J, Cen K, Zhang J, Zhang H, Zhao M, Hou X. Uric acid levels and heart failure: a mendelian randomization study. Nutr Metab Cardiovasc Dis. 2024; 34: 1008-13.

[69] Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107: 1991-7.

[70] Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al.; NHLBI Heart Failure Clinical Research Network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015; 131: 1763-71.

[71] Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014; 11: 1102-8.

[72] Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2011; 108: 1272-6.

[73] Mantovani A, Rigolon R, Pichiri I, Morani G, Bonapace S, Dugo C, et al. Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. J Diabetes Complications. 2017; 31: 1691-7.

[74] Tang RB, Dong JZ, Yan XL, Du X, Kang JP, Wu JH, et al. Serum uric acid and risk of left atrial thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2014; 30: 1415-21.

[75] Celik M, Yalcinkaya E, Yuksel UC, Gokoglan Y, Bugan B, Kabul HK, et al. Increased serum uric acid levels are correlated with decreased left atrial appendage peak flow velocity in patients with atrial fibrillation. Med Princ Pract. 2015; 24: 263-8.

[76] Maharani N, Kuwabara M, Hisatome I. Hyperuricemia and atrial fibrillation. Int Heart J. 2016; 57: 395-9.

[77] Maharani N, Ting YK, Cheng J, Hasegawa A, Kurata Y, Li P, et al. Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes. Circ J. 2015; 79: 2659-68.

[78] Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the rotterdam study. Stroke. 2006; 37: 1503-7.

[79] Centola M, Maloberti A, Castini D, Persampieri S, Sabatelli L, Ferrante G, et al. Impact of admission serum acid uric levels on in-hospital outcomes in patients with acute coronary syndrome. Eur J Intern Med. 2020; 82: 62-7.

[80] Sathvik M, Kalva ECSS, Suma G. A study on acute myocardial infarction and its prognostic predictors. Cureus. 2023; 15: e34775.

[81] Dyrbuś M, Desperak P, Pawełek M, Możdżeń M, Gąsior M, Hawranek M. Serum uric acid is an independent risk factor of worse mid- and long-term outcomes in patients with non-ST-segment elevation acute coronary syndromes. Cardiol J. 2021; 30: 984-94.

[82] Kumar N, Kumar H, Kumar V, Nayyer PS. A study of the serum uric acid level as prognostic indicator in acute myocardial infarction. J Assoc Physicians India. 2020; 68: 31-4.

[83] Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF. Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern Emerg Med. 2012; 7: 33-9. Erratum in: Intern Emerg Med. 2017;12:275- 7.

[84] Kaya MG, Uyarel H, Akpek M, Kalay N, Ergelen M, Ayhan E, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012; 109: 486-91.

[85] Cimmino G, Gallinoro E, di Serafino L, De Rosa G, Sugraliyev A, Golino P, et al. Uric acid plasma levels are associated with C-reactive protein concentrations and the extent of coronary artery lesions in patients with acute coronary syndromes. Intern Emerg Med. 2023; 18: 1751-7.

[86] Okazaki H, Shirakabe A, Matsushita M, Shibata Y, Sawatani T, Uchiyama S, et al. Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care. ESC Heart Fail. 2019; 6: 336-43.

[87] Okura T, Higaki J, Kurata M, Irita J, Miyoshi K, Yamazaki T, et al.; Japanese Coronary Artery Disease Study Investigators. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2009; 73: 885-91.

[88] Tian TT, Li H, Chen SJ, Wang Q, Tian QW, Zhang BB, et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a case-control study. Dis Markers. 2018; 2018: 1236837.

[89] Karabağ Y, Rencuzogullari I, Çağdaş M, Karakoyun S, Yesin M, Atalay E, et al. Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and/or unprotected left main disease. Int J Cardiovasc Imaging. 2019; 35: 1-7.

[90] Tasić I, Kostić S, Stojanović NM, Skakić V, Cvetković J, Djordjević A, et al. Significance of asymptomatic hyperuricemia in patients after coronary events. Scand J Clin Lab Invest. 2018; 78: 312-7.

[91] Zand S, Shafiee A, Boroumand M, Jalali A, Nozari Y. Serum uric acid is not an independent risk factor for premature coronary artery disease. Cardiorenal Med. 2013; 3: 246-53.

[92] Maloberti A, Bossi I, Tassistro E, Rebora P, Racioppi A, Nava S, et al. Uric acid in chronic coronary syndromes: relationship with coronary artery disease severity and left ventricular diastolic parameter. Nutr Metab Cardiovasc Dis. 2021; 31: 1501-8.

[93] Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al.; ALL-HEART Study Group. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022; 400: 1195-205.

[94] Padda J, Khalid K, Padda S, Boddeti NL, Malhi BS, Nepal R, et al. Hyperuricemia and its association with ischemic stroke. Cureus. 2021; 13: e18172.

[95] Qiao T, Wu H, Peng W. The relationship between elevated serum uric acid and risk of stroke in adult: an updated and dose-response meta-analysis. Front Neurol. 2021; 12: 674398.

[96] Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009; 61: 885-92.

[97] Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002; 33: 1048-52.

[98] McAdams-DeMarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident hyperuricemia during mid-adulthood in African American and White men and women enrolled in the ARIC cohort study. BMC Musculoskelet Disord. 2013; 14: 347.

[99] Chaudhary NS, Bridges SL Jr, Saag KG, Rahn EJ, Curtis JR, Gaffo A, et al. Severity of hypertension mediates the association of hyperuricemia with stroke in the REGARDS case cohort study. Hypertension. 2020; 75: 246-56.

[100] Tu W, Wu J, Jian G, Lori J, Tang Y, Cheng H, et al. Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities. Eur J Clin Nutr. 2019; 73: 1392-402.

[101] Larsen KS, Pottegård A, Lindegaard HM, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016; 129: 299-306.e2.

[102] Singh JA, Yu S. Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurol. 2016; 16: 164.

[103] El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: a review. J Adv Res. 2017; 8: 487-93.

[104] Tian X, Chen S, Zhang Y, Zhang X, Xu Q, Wang P, et al. Serum uric acid variation and the risk of cardiovascular disease: a prospective cohort study. Eur J Intern Med. 2023; 112: 37-44.

[105] Katsiki N, Dimitriadis GD, Mikhailidis DP. Serum uric acid and diabetes: from pathophysiology to cardiovascular disease. Curr Pharm Des. 2021; 27: 1941-51.

[106] Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981; 78: 6858-62.

[107] Sugihara S, Hisatome I, Kuwabara M, Niwa K, Maharani N, Kato M, et al. Depletion of uric acid due to SLC22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia. Circ J. 2015; 79: 1125-32.

[108] Iso T, Kurabayashi M. Extremely low levels of serum uric acid are associated with endothelial dysfunction in humans. Circ J. 2015; 79: 978-80.

[109] Nery RA, Kahlow BS, Skare TL, Tabushi FI, do Amaral e Castro A. Uric acid and tissue repair. Arq Bras Cir Dig. 2015; 28: 290-2.

[110] Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity. 2011; 34: 527-40. Erratum in: Immunity. 2011; 34:627.

[111] Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1998; 95: 675-80.

[112] Chakraborti G, Biswas R, Chakraborti S, Sen PK. Altered serum uric acid level in lichen planus patients. Indian J Dermatol. 2014; 59: 558-61.

[113] Cimmino G, Muscoli S, De Rosa S, Cesaro A, Perrone MA, Selvaggio S, et al.; Pathogenesis Of Atherosclerosis Working Group Of The Italian Society Of Cardiology. Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation. J Cardiovasc Med (Hagerstown). 2023; 24: e156-67.

[114] Nakanishi K, Morita H. Uric acid. Int Heart J. 2022; 63: 423-5.

[115] Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004; 555: 589-606.

[116] Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012; 33: 829-37.

[117] Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999; 274: 4985-94.

[118] Panus PC, Wright SA, Chumley PH, Radi R, Freeman BA. The contribution of vascular endothelial xanthine dehydrogenase/oxidase to oxygen-mediated cell injury. Arch Biochem Biophys. 1992; 294: 695-702.

[119] Kushiyama A, Okubo H, Sakoda H, Kikuchi T, Fujishiro M, Sato H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol. 2012; 32: 291-8.

[120] Ko J, Kang HJ, Kim DA, Kim MJ, Ryu ES, Lee S, et al. Uric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative stress and glycocalyx shedding. FASEB J. 2019; 33: 13334-45.

[121] Jedlicka J, Becker BF, Chappell D. Endothelial glycocalyx. Crit Care Clin. 2020; 36: 217-32.

[122] Ramnath R, Foster RR, Qiu Y, Cope G, Butler MJ, Salmon AH, et al. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor α: a contributor to endothelial cell glycocalyx dysfunction. FASEB J. 2014; 28: 4686-99.

[123] Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, et al. Human vascular smooth muscle cells express a urate transporterr. J Am Soc Nephrol. 2006; 17: 1791-5.

[124] Otani N, Ouchi M, Misawa K, Hisatome I, Anzai N. Hypouricemia and urate transporters. Biomedicines. 2022; 10: 652.

[125] Cai W, Duan XM, Liu Y, Yu J, Tang YL, Liu ZL, et al. Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway. Biomed Res Int. 2017; 2017: 4391920.

[126] Liang WY, Zhu XY, Zhang JW, Feng XR, Wang YC, Liu ML. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. Nutr Metab Cardiovasc Dis. 2015; 25: 187-94.

[127] Russo E, Verzola D, Cappadona F, Leoncini G, Garibotto G, Pontremoli R, et al. The role of uric acid in renal damage - a history of inflammatory pathways and vascular remodeling. Vessel Plus. 2021; 5: 15.

[128] Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005; 25: 425-33.

[129] Mishima M, Hamada T, Maharani N, Ikeda N, Onohara T, Notsu T, et al. Effects of uric acid on the NO production of HUVECs and its restoration by urate lowering agents. Drug Res (Stuttg). 2016; 66: 270-4.

[130] Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010; 28: 1234-42.

[131] Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008; 21: 1157-62.

[132] Miyazaki S, Sakuragi T, Hamada T, Sugihara S, Park D, Inoue K, et al. Effects of irbesartan on uric acid metabolism in patients with treated essential hypertension. Vasc Failure. 2018; 2: 11-9.

[133] Țăpoi L, Șalaru DL, Sascău R, Stătescu C. Uric acid-an emergent risk marker for thrombosis? J Clin Med. 2021; 10: 2062.

[134] Cimmino G, Di Serafino L, Cirillo P. Pathophysiology and mechanisms of acute coronary syndromes: atherothrombosis, immune-inflammation, and beyond. Expert Rev Cardiovasc Ther. 2022; 20: 351-62.

[135] Cimmino G, Conte S, Marra L, Morello A, Morello M, De Rosa G, et al. Uric acid induces a proatherothrombotic phenotype in human endothelial cells by imbalancing the tissue factor/tissue factor pathway inhibitor pathway. Thromb Haemost. 2023; 123: 64-75.

[136] Weng H, Li H, Zhang Z, Zhang Y, Xi L, Zhang D, et al. Association between uric acid and risk of venous thromboembolism in East Asian populations: a cohort and Mendelian randomization study. Lancet Reg Health West Pac. 2023; 39: 100848.

[137] Yu M, Ling K, Teng Y, Li Q, Mei F, Li Y, et al. Serum uric acid is associated with increased risk of idiopathic venous thromboembolism in high HDL-C population: a case-control study. Exp Ther Med. 2016; 11: 2314-20.

[138] Huang CC, Huang PH, Chen JH, Lan JL, Tsay GJ, Lin HY, et al. An independent risk of gout on the development of deep vein thrombosis and pulmonary embolism: a nationwide, population-based cohort study. Medicine (Baltimore). 2015; 94: e2140.

[139] De Lucchi L, Nardin C, Sponchiado A, Raggi D, Faggin E, Martini E, et al. Serum uric acid levels and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2021; 19: 194-201.

[140] Sincer I, Gunes Y, Mansiroglu AK, Aktas G. Differential value of eosinophil count in acute coronary syndrome among elderly patients. Aging Male. 2020; 23: 958-61.

[141] Aktas G, Yilmaz S, Kantarci DB, Duman TT, Bilgin S, Balci SB, et al. Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury? Postgrad Med. 2023; 135: 519-23.

[142] Kurtkulagi O, Tel BMA, Kahveci G, Bilgin S, Duman TT, Ertürk A, et al. Hashimoto’s thyroiditis is associated with elevated serum uric acid to high density lipoprotein-cholesterol ratio. Rom J Intern Med. 2021; 59: 403-8.

[143] Kosekli MA, Kurtkulagii O, Kahveci G, Duman TT, Tel BMA, Bilgin S, et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev Assoc Med Bras (1992). 2021; 67: 549-54.

[144] Zhang H, Ma Y, Cao R, Wang G, Li S, Cao Y, et al. Soluble uric acid induces myocardial damage through activating the NLRP3 inflammasome. J Cell Mol Med. 2020; 24: 8849-61.

[145] Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011; 469: 221-5. Erratum in: Nature. 2011;475:122.

[146] Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019; 10: 128.

[147] Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014; 11: 255-65.

[148] Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017; 7: 39884.

[149] Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol. 2020; 40: 570-82.

[150] Aktas G, Khalid A, Kurtkulagi O, Duman TT, Bilgin S, Kahveci G, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med. 2022; 134: 297-302.

[151] Kocak MZ, Aktas G, Erkus E, Sincer I, Atak B, Duman T. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras (1992). 2019; 65: 9-15.

[152] Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020; 23: 1098-102.

[153] Kosekli MA, Aktas G. Serum uric acid to HDL cholesterol ratio is associated with diabetic control in new onset type 2 diabetic population. Acta Clin Croat. 2023; 62: 277-82.

[154] Balci SB, Atak BM, Duman T, Ozkul FN, Aktas G. A novel marker for prediabetic conditions: uric acid-to-HDL cholesterol ratio. Bratisl Lek Listy. 2024; 125: 145-8.

[155] Cheng Y, Zhang H, Zheng H, Yin H, Wang Y, Wang H, et al. Association between serum uric acid/HDL-cholesterol ratio and chronic kidney disease: a cross-sectional study based on a health check-up population. BMJ Open. 2022; 12: e066243.